JP2019535241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535241A5 JP2019535241A5 JP2019520556A JP2019520556A JP2019535241A5 JP 2019535241 A5 JP2019535241 A5 JP 2019535241A5 JP 2019520556 A JP2019520556 A JP 2019520556A JP 2019520556 A JP2019520556 A JP 2019520556A JP 2019535241 A5 JP2019535241 A5 JP 2019535241A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- sequence
- antigen
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 129
- 229920001184 polypeptide Polymers 0.000 claims description 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 114
- 239000000427 antigen Substances 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 39
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 102200104166 rs11540652 Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000002933 Thioredoxin Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229940094937 thioredoxin Drugs 0.000 claims description 4
- 108060008226 thioredoxin Proteins 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 3
- 238000009566 cancer vaccine Methods 0.000 claims description 3
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 102200101620 rs104894442 Human genes 0.000 claims description 3
- 102200106084 rs1057519991 Human genes 0.000 claims description 3
- 102200069225 rs121434640 Human genes 0.000 claims description 3
- 102200104161 rs121912651 Human genes 0.000 claims description 3
- 102200106274 rs121912656 Human genes 0.000 claims description 3
- 102200068968 rs200188353 Human genes 0.000 claims description 3
- 102200057536 rs202160435 Human genes 0.000 claims description 3
- 102200059506 rs281875236 Human genes 0.000 claims description 3
- 102200104847 rs28934574 Human genes 0.000 claims description 3
- 102200106275 rs28934575 Human genes 0.000 claims description 3
- 102200106083 rs587780070 Human genes 0.000 claims description 3
- 102200016737 rs72552294 Human genes 0.000 claims description 3
- 102200102859 rs786202962 Human genes 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 2
- 230000027455 binding Effects 0.000 description 88
- 239000012634 fragment Substances 0.000 description 81
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 21
- 102200102887 rs28934578 Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 102200104041 rs28934576 Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1617564.8 | 2016-10-17 | ||
| GBGB1617564.8A GB201617564D0 (en) | 2016-10-17 | 2016-10-17 | Anti-p53 antibodies |
| PCT/SG2017/050522 WO2018074978A1 (en) | 2016-10-17 | 2017-10-17 | Anti-p53 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535241A JP2019535241A (ja) | 2019-12-12 |
| JP2019535241A5 true JP2019535241A5 (enExample) | 2020-11-26 |
| JP7173964B2 JP7173964B2 (ja) | 2022-11-16 |
Family
ID=57680660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520556A Active JP7173964B2 (ja) | 2016-10-17 | 2017-10-17 | 抗ｐ５３抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11613568B2 (enExample) |
| EP (1) | EP3526251A4 (enExample) |
| JP (1) | JP7173964B2 (enExample) |
| CN (1) | CN110770252A (enExample) |
| GB (1) | GB201617564D0 (enExample) |
| SG (1) | SG11201903411YA (enExample) |
| WO (1) | WO2018074978A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234452B2 (en) * | 2016-12-27 | 2022-02-01 | Hills Pet Nutrition, Inc. | Pet food compositions |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| GB202008688D0 (en) | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN113403286B (zh) * | 2021-06-24 | 2024-01-16 | 新乡学院 | 一种靶向性三展示噬菌体及其制备方法和应用 |
| EP4412650A1 (en) * | 2021-10-05 | 2024-08-14 | The Penn State Research Foundation | Methods for treating cancers with mutated p53 |
| CN116178501B (zh) * | 2021-11-29 | 2025-08-29 | 深圳碳云智肽药物科技有限公司 | 靶向p53的多肽及其在制备用于治疗癌症的药物中的应用 |
| US20250034252A1 (en) * | 2021-12-16 | 2025-01-30 | The Johns Hopkins University | Manabodies targeting p53 tumor antigens and methods of using |
| TW202340474A (zh) * | 2022-01-11 | 2023-10-16 | 大陸商深圳市珈鈺生物科技有限公司 | 樹突細胞腫瘤疫苗和其用途 |
| CN114574524A (zh) * | 2022-03-14 | 2022-06-03 | 深圳市体内生物医药科技有限公司 | 一种从全基因组中筛选肝癌抑癌基因的方法及其应用 |
| EP4669328A1 (en) * | 2023-02-22 | 2025-12-31 | Elysion Therapeutics, Inc. | LYSIS DETECTION RECEIVERS AND RELATED USES |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025259636A1 (en) * | 2024-06-10 | 2025-12-18 | Baylor College Of Medicine | Targeting p53 mutants |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083709A (en) | 1985-08-21 | 2000-07-04 | Osi Pharmaceuticals, Inc. | Immunoassay for detection of mutant P53 polypeptide in serum |
| WO1992013970A1 (en) | 1991-02-01 | 1992-08-20 | Oncogene Science, Inc. | Immunoassay for detection of mutant p53 polypeptide in biological fluids |
| DE69133528T2 (de) | 1990-06-27 | 2006-09-07 | Princeton University | Proteinkomplex p53/p90 |
| US5646016A (en) | 1991-02-06 | 1997-07-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules |
| EP1421947A1 (en) * | 1992-07-22 | 2004-05-26 | The Trustees Of Princeton University | p53 vaccine |
| US20030086935A1 (en) * | 1992-07-22 | 2003-05-08 | Levine Arnold J. | p53 vaccine |
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| WO2006100681A2 (en) | 2005-03-25 | 2006-09-28 | Ramot At Tel Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| EP2268658B1 (en) * | 2008-03-13 | 2015-12-09 | Universita'Degli Studi di Trieste | Peptides and aptamers thereof as specific modulators of mutant p53 function |
| WO2010120514A2 (en) * | 2009-03-31 | 2010-10-21 | The Trustees Of The University Of Pennsylvania | Antigen-binding proteins comprising recombinant protein scaffolds |
| SG10201601840RA (en) | 2011-09-09 | 2016-04-28 | Agency Science Tech & Res | P53 activating peptides |
-
2016
- 2016-10-17 GB GBGB1617564.8A patent/GB201617564D0/en not_active Ceased
-
2017
- 2017-10-17 SG SG11201903411YA patent/SG11201903411YA/en unknown
- 2017-10-17 EP EP17861395.6A patent/EP3526251A4/en active Pending
- 2017-10-17 WO PCT/SG2017/050522 patent/WO2018074978A1/en not_active Ceased
- 2017-10-17 US US16/342,763 patent/US11613568B2/en active Active
- 2017-10-17 JP JP2019520556A patent/JP7173964B2/ja active Active
- 2017-10-17 CN CN201780078161.4A patent/CN110770252A/zh active Pending
-
2023
- 2023-02-22 US US18/172,773 patent/US12195526B2/en active Active
-
2024
- 2024-11-27 US US18/961,716 patent/US20250263475A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Targeting aging and age-related diseases with vaccines | |
| Zeltins et al. | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy | |
| ES2585702T3 (es) | Composiciones y métodos para la unión al ácido lisofosfatídico | |
| ES3048696T3 (en) | Ror1 antibodies | |
| CA2885924C (en) | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein | |
| WO2020253643A1 (zh) | 肿瘤新抗原多肽及其用途 | |
| JP2016524592A5 (enExample) | ||
| WO2014206304A1 (zh) | 高稳定性的t细胞受体及其制法和应用 | |
| JP2002528393A5 (enExample) | ||
| AU2017335991A1 (en) | Neutralizing antibodies to the αVβ8 integrin complex for immunotherapy | |
| JP2024507540A5 (enExample) | ||
| HK1259325A1 (zh) | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 | |
| EP4069745A1 (en) | Compositions and methods for transferrin receptor 1 targeting | |
| EP3004173B1 (en) | Single domain antibody display | |
| KR20110071117A (ko) | 변성된 아밀로이드 베타 펩티드 | |
| US20240228549A1 (en) | Prefusion-stabilized lassa virus glycoprotein complex and its use | |
| CN122003713A (zh) | 用于选择个性化新抗原疫苗的计算方法 | |
| WO2013152274A1 (en) | Epitope- scaffold immunogens against respiratory syncytial virusm (rsv) | |
| Mariano et al. | A two-component cocktail of engineered DIII nanoparticles elicits broadly neutralizing antibody responses against dengue virus in mice | |
| WO2022180409A1 (en) | Diagnostic method using ige molecules | |
| WO2024173551A2 (en) | Tryptophan neoantigen peptides for diagnostics, therapeutics, and vaccines | |
| JP6030650B2 (ja) | ポリオーマウイルス関連病態を阻害するための方法および組成物 | |
| CN115260306A (zh) | 靶向SARS-CoV-2受体结合基序的单克隆抗体及其识别抗原表位和应用 | |
| US20260069679A1 (en) | Coronavirus spike protein-based vaccines | |
| US20250032605A1 (en) | Rationally designed immunogens |